Successful Crizotinib-Targeted Therapy of Pediatric Unresectable
ERC1::ALK Fusion Sarcoma
Abstract
Anaplastic lymphoma kinase ( ALK)-fusion sarcomas are
rare, part of the emerging theoretically-targetable tyrosine-kinase
RAS::MAPK-pathway fusion myopericytic-ovoid-sarcomas. We report
our clinicopathologic and treatment experience with an ALK-fusion
sarcoma. A novel ERC1-unaligned-ALK-fusion infiltrative
nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male
was treated with crizotinib, an ALK tyrosine-kinase inhibitor as
oral monotherapy, inducing complete radiographic and clinical resolution
by 10 months and sustained response now 8 months after elective
discontinuation. Crizotinib can successfully be used to treat
unresectable novel ALK-fusion sarcomas.